Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook

Corbus Pharmaceuticals ( (CRBP) ) has shared an update.

Corbus Pharmaceuticals presented an updated corporate overview dated February 25, 2026, highlighting a diversified pipeline led by CRB-701, a next-generation Nectin-4–targeting ADC designed for longer half-life, reduced free MMAE exposure, fewer PADCEV-associated toxicities, and a best-in-class dosing regimen, with ongoing studies in head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial carcinoma across the U.S. and Europe. The company also underscored upcoming 2026 milestones, including 12-week dose-range finding data for CRB-913 in obesity, dose-escalation data for CRB-601 in αvβ8-enriched solid tumors, and emerging ESMO 2025 data showing a favorable safety profile for CRB-701 versus Nectin-4–MMAE peers, supported by a cash position of $173 million as of November 3, 2025, and a relatively low share count, which collectively reinforce its financial capacity and strategic positioning in competitive oncology and metabolic disease markets.

The most recent analyst rating on (CRBP) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Spark’s Take on CRBP Stock

According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.

The score is held back primarily by weak financial performance (no revenue, sizable losses and cash burn) and bearish technical signals (below major moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and positive recent corporate events around pipeline progress and financing that may improve operating runway into upcoming clinical milestones.

To see Spark’s full report on CRBP stock, click here.

More about Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing novel therapeutics for solid tumors and metabolic diseases. Its pipeline includes CRB-701, a next-generation Nectin-4–targeting antibody-drug conjugate for Nectin-4–positive solid tumors, CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for obesity and related conditions, and CRB-601, an anti-αvβ8 monoclonal antibody targeting TGFβ in αvβ8-enriched solid tumors. The company is pursuing U.S. and European development for CRB-701, with Fast Track designation in head and neck squamous cell carcinoma and cervical cancer, and is advancing a differentiated portfolio aimed at oncology and obesity markets.

Average Trading Volume: 270,904

Technical Sentiment Signal: Sell

Current Market Cap: $133.9M

Find detailed analytics on CRBP stock on TipRanks’ Stock Analysis page.